| https://link.springer.com/article/10.1208/s12248-023-00852-z |
The identification and removal of host cell proteins (HCPs) from biologic products is a critical step in drug development. Despite recent improvements to purification processes, biologics such as monoclonal antibodies, enzyme replacement therapies, and vaccines that are manufactured in a range of cell lines and purified using diverse processes may contain HCP impurities, making it necessary for developers to identify and quantify impurities during process development for each drug product. HCPs that contain sequences that are less conserved with human homologs may be more immunogenic than those that are more conserved. We have developed a computational tool, ISPRI-HCP, that estimates the immunogenic potential of HCP sequences by evaluating and quantifying T cell epitope density and relative conservation with similar T cell epitopes in the human proteome. Here we describe several case studies that support the use of this method for classifying candidate HCP impurities according to their immunogenicity risk.
To view the full article through your AAPS membership:
Go to https://www.aaps.org/education-and-research/journals/the-aaps-journal. Click or tap if you trust this link." rel="noopener">https://www.aaps.org/education-and-research/journals/the-aaps-journal
Enter your AAPS credentials
Click "Member Access to Journals"
Click on the The AAPS Journal cover.
Copy and paste the url into the "Search" box, and click search
The full article should appear.
Follow The AAPS Journal via Twitter: https://twitter.com/theaapsjournal
and by Linkedin, https://www.linkedin.com/showcase/theaapsjournal/
------------------------------
Ho-Leung Fung Ph.D., FAAPS
Editor-in-Chief
University at Buffalo
Sarasota FL
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------